i-Pharm GxP

Last week, we asked for your opinions on direct-to-consumer pharmaceutical ads and a recent study that has shown a split opinion on the ethics behind this. 🤔 Our poll results align with the study and show that opinions are clearly divided between being supportive and being opposed with a complete 50/50 split down the middle. Are these ads a vital source of information, or are unintended consequences too high of a risk? ________________ Leave your thoughts on these results in the comment section below! #pharmaceutical #patienteducation #iPharmGxP

Have you caught up on the #GxPodcast yet?🎙️ Tune in as Eckart W Schwarz, MD shares insights from his 30+ years in drug development, regulatory affairs, and clinical management across the globe. We explored the latest trends in R&D, the role of AI, and the strategic complexities of offshoring in biopharma. ___________________ Listen to the full episode here: 🔗 https://lnkd.in/erEqknvU #drugdevelopment #iPharmGxP

Thrilled to share a recent success story where our team provided comprehensive project management and oversight for CapEx and construction projects across multiple sites. From initial concept to final close-out, our team ensured smooth execution and compliance, driving impactful results for a leading pharmaceutical client. 🚀 _______________ Have a look at the slides below to read more about how we saw this project through. #iPharmGxP #pharmaceutical #casestudy

Last week, we posted about direct-to-consumer pharmaceutical ads and a recent study that has shown a split opinion on the ethics behind this. 🤔 Opinions are currently divided on the value and impact of these ads. Some see them as a vital source of information, while others are concerned about the potential risks and unintended consequences. How do you feel about direct-to-consumer pharmaceutical ads? 1️⃣ Support: They provide essential information and empower patients 2️⃣ Oppose: They can lead to unnecessary treatments and misunderstandings 3️⃣ Neutral: The impact varies and depends on individual cases Vote in the poll below and leave your thoughts in the comment section! #pharmaceutical #patienteducation #iPharmGxP

Compliance and quality systems are evolving fast in the world of advanced therapies. In Episode 5 of the #GxPodcast, Carlos Yuraszeck shares his wealth of experience from nearly three decades in pharma and biotech. 🎙️ Our team discuss how compliance has shifted from fault-finding to embracing best practices, the challenges of CAR-T cell therapies, and the role of AI in the future of cell therapies. Don’t miss Carlos’ expert insights and actionable strategies for enhancing compliance and innovation in our industry. ______________ Listen here: 🔗 https://lnkd.in/e4fNWc_B #iPharmGxP #lifesciences #compliance 

Check out the document below to read about a recent project we completed with a leading pharmaceutical company. 🚀 The client needed support integrating a new fill-finish line into their sterile manufacturing facility. Our team managed the entire validation process, including Installation Qualification (IQ) and Operational Qualification (OQ), ensuring seamless integration. We also validated Performance Qualification (PQ), achieving 100% regulatory compliance and increasing production capacity by 35% to meet market demands. _____________ Have a project in mind? Get in touch with us today to see how we can assist with your business needs! #pharmaceuticals #iPharmGxP #casestudy

A recent study by ZoomRx sheds light on an interesting topic in our industry: should direct-to-consumer pharmaceutical ads be banned in the U.S.? 🤔 The study found that 50% of doctors and 58% of patients find these ads “somewhat” or “extremely” helpful. Many believe the ads provide valuable information on health conditions and treatments, sparking important conversations between patients and doctors. However, while some see these ads as educational, others worry about the emphasis on potential side effects and the risk of patients requesting unsuitable treatments. __________________ Where do you stand in this 50/50 split? Leave your thoughts in the comments below. 💬 #iPharmGxP #pharmaceuticals #lifesciences

Data management and technology are at the heart of modern drug development. In Episode 7 of the #GxPodcast, the team discuss how AI, machine learning, and automation are transforming the life sciences industry. 🤖 Learn about the importance of data integrity, quality, and organisation in drug development, and how these innovations are helping to bring hope to patients through cutting-edge therapies. The team also share insights on the concept of longevity escape velocity and its potential impact on the future of healthcare. _________________ Tune in here: 🔗 https://lnkd.in/epPWCX7p #AI #datamanagement #iPharmGxP

Merck, AstraZeneca, and Gilead are leading the race in developing antibody-drug conjugates (ADCs), a promising cancer treatment. These three companies collectively have 33 Phase 3 clinical trials underway, indicating their strong commitment and competitive edge in the ADC field. ADCs are innovative therapies that combine antibodies with potent anti-cancer drugs to target and destroy cancer cells more effectively while minimizing damage to healthy cells. This competition highlights the intense focus on advancing cancer treatments in our industry with the potential for significant impacts on patient outcomes. We are looking forward to keeping up to date with further developments. __________ Leave your thoughts on these developments in the comments below. 💬 #ADC #iPharmGxP 

Last week, we asked for your opinion on a drug that could potentially elongate women's fertility in the future. Rapamycin's promising results in extending women's fertility and improving overall health have sparked much interest and debate. The results are in, and with half of you voting for 'cautiously optimistic' we are intrigued to see how successful the drug is on it's second round of testing. #Rapamycin #iPharmGxP #medicaldevelopments